Skip to main content
Premium Trial:

Request an Annual Quote

Pressure BioSciences Completes Second Tranche of Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences said after the close of the market Tuesday that it has completed the second tranche of its private placement raising gross proceeds of $275,475.

In the second tranche of the offering, the firm sold 22,038 units to two accredited investors for $12.50 per unit. Each unit consists of one share of Series C convertible preferred stock, which is convertible into 10 shares of common stock, and a warrant to purchase 10 shares of common stock at an exercise price equal to $2.13 per share, which is exercisable until the third anniversary of the date of issuance.

Pressure Bio disclosed in the filing with the US Securities and Exchange Commission that it had entered into an agreement with the investors to lower the price of the units from $15 each to $12.50 each. As a result, the firm issued an additional 11,011 units to investors who participated in the earlier closings on April 8 and April 11.

Pressure Bio has raised total gross proceeds of $1.1 million thus far from the private placement.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.